Hiroshi Shigematsu
Overview
Explore the profile of Hiroshi Shigematsu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
1035
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nagafuchi H, Kikuchi H, Ishibash H, Maeda H, Ogino H, Kirino Y, et al.
Mod Rheumatol
. 2023 Jan;
34(1):182-193.
PMID: 36658731
Objectives: This study aimed to develop clinical guidelines for the management of vascular Behçet's disease (BD) by the Behçet's Disease Research Committee of the Ministry of Health, Labour and Welfare...
2.
Isobe M, Amano K, Arimura Y, Ishizu A, Ito S, Kaname S, et al.
Circ J
. 2020 Jan;
84(2):299-359.
PMID: 31956163
No abstract available.
3.
Higashi Y, Miyata T, Shigematsu H, Origasa H, Fujita M, Matsuo H, et al.
Circ J
. 2019 Jul;
83(9):1929-1936.
PMID: 31292312
Background: Guidelines for peripheral arterial disease (PAD) recommend long-term antiplatelet therapy in symptomatic patients to reduce cardiovascular morbidity and mortality risk. Although diabetes is a known risk factor for PAD,...
4.
Akai A, Shigematsu H, Miyata T, Maeda H, Onohara T, Sato O, et al.
Ann Vasc Dis
. 2019 Jul;
12(2):182-186.
PMID: 31275471
: This multicenter observational study was conducted in order to investigate the incidence of cancer in patients with critical limb ischemia. : We prospectively investigated the incidence of cancer in...
5.
Miyata T, Higashi Y, Shigematsu H, Origasa H, Fujita M, Matsuo H, et al.
Angiology
. 2018 Nov;
70(6):506-514.
PMID: 30477334
Surveillance of cardiovascular Events in Antiplatelet-treated arterioSclerosis Obliterans patients in JapaN (SEASON) is a 2-year, prospective, real-world, registry study conducted in Japan from 2009 to 2013. This post hoc analysis...
6.
Chiba Y, Yamakawa T, Tsuchiya H, Oba M, Suzuki D, Danno H, et al.
J Clin Med Res
. 2018 Jul;
10(8):648-656.
PMID: 29977423
Background: Anagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor expected to improve the lipid profile as well as glycemic control. However, findings from large-scale prospective trials have not been obtained. Methods:...
7.
Jibiki M, Miyata T, Shigematsu H
J Vasc Surg Cases Innov Tech
. 2018 Jun;
4(2):136-139.
PMID: 29942903
Cystic adventitial disease (CAD) of the popliteal artery with spontaneous regression is rare. We describe a 44-year-old man with rapid onset of severe intermittent claudication who is currently undergoing conservative...
8.
Higashi Y, Miyata T, Shigematsu H, Origasa H, Fujita M, Matsuo H, et al.
Sci Rep
. 2017 Jul;
7(1):6095.
PMID: 28733607
The present analysis was intended to evaluate the real-world management of peripheral arterial disease (PAD) in Asia, and to explore cardiovascular events in patients with PAD undergoing antiplatelet therapy over...
9.
Komai H, Shindo S, Shigematsu H, Ogino H
J Cardiovasc Surg (Torino)
. 2016 Apr;
57(3):481-2.
PMID: 27094428
No abstract available.
10.
Higashi Y, Miyata T, Shigematsu H, Origasa H, Fujita M, Matsuo H, et al.
Circ J
. 2016 Feb;
80(3):712-21.
PMID: 26841805
Background: Despite mounting evidence of increased cardiovascular events in patients with peripheral arterial disease (PAD), the overall incidence of cardiovascular events in PAD patients has not been fully clarified in...